Options of dyslipidemia treatment at non-alcoholic fatty liver disease
Aim of review. To consider different treatment options for dyslipidemia in non-alcoholic fatty liver disease (NAFLD). Summary. NAFLD occurs in 20-30% of adult population. In the Russian Federation its rate is estimated as high as 37,1%. In the most of NAFLD cases severe disorder of lipid metabolism...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Gastro LLC
2018-08-01
|
| Series: | Российский журнал гастроэнтерологии, гепатологии, колопроктологии |
| Subjects: | |
| Online Access: | https://www.gastro-j.ru/jour/article/view/71 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823860259554328576 |
|---|---|
| author | M. V. Mayevskaya M. A. Morozova |
| author_facet | M. V. Mayevskaya M. A. Morozova |
| author_sort | M. V. Mayevskaya |
| collection | DOAJ |
| description | Aim of review. To consider different treatment options for dyslipidemia in non-alcoholic fatty liver disease (NAFLD). Summary. NAFLD occurs in 20-30% of adult population. In the Russian Federation its rate is estimated as high as 37,1%. In the most of NAFLD cases severe disorder of lipid metabolism takes place. In large clinical trials it was demonstrated that the dyslipidemia significantly increases cardiovascular risks and worsens life expectancy in these patients. In the present overview treatment options of several therapeutic agents for dyslipidemia treatment at NAFLD are discussed: phenofibrate, omega-3 polyunsaturated fatty acids (omega-3-PUFAs) and S-adenosylmethionine (SAM). Results of numerous experiments and several clinical trials form the basis for phenofibrate administration for NAFLD patients. In animal experiments the positive role of phenofibrate as PPARα agonist was demonstrated (Peroxisome proliferator activated receptor alpha) for NAFLD prevention and treatment. Results of several studies published at the moment demonstrate that at NAFLD lipid metabolism markers, and serum transaminase levels normalize, sensitivity to insulin increases, the liver histology pattern improves at phenofibrate treatment. Specification of efficacy and safety of application of the drug requires more large-scale clinical studies. Omega-3-PUFAs is one more option in the lipid metabolism disorders treatment in this group of patients. These substances play important role in lipid metabolism regulating expression of the genes (including PPARα) involved in lipid and glucose metabolism. Available clinical trials demonstrate high therapeutical effect of these agents at NAFLD. In the review results of the experimental studies investigating the role of SAM in NAFLD pathogenesis and disorders of lipid metabolism is presented. Conclusion. Now data on a pathogenesis of lipid metabolism disorders at NAFLD are accumulated. The bulk of experimental data and series of clinical trials allow to assume positive affect of such drugs as phenofibrate, omega-3-PUFA and SAMe for treatment of dyslipidemia. Further high-grade studies in this area is necessary. |
| format | Article |
| id | doaj-art-233cdd5650d243ed9c8a52c8f85a88db |
| institution | Kabale University |
| issn | 1382-4376 2658-6673 |
| language | Russian |
| publishDate | 2018-08-01 |
| publisher | Gastro LLC |
| record_format | Article |
| series | Российский журнал гастроэнтерологии, гепатологии, колопроктологии |
| spelling | doaj-art-233cdd5650d243ed9c8a52c8f85a88db2025-02-10T16:14:28ZrusGastro LLCРоссийский журнал гастроэнтерологии, гепатологии, колопроктологии1382-43762658-66732018-08-01264556110.22416/1382-4376-2016-4-55-6171Options of dyslipidemia treatment at non-alcoholic fatty liver diseaseM. V. Mayevskaya0M. A. Morozova1State educational government-financed institution of higher professional education «Sechenov First Moscow state medical university»State educational government-financed institution of higher professional education «Sechenov First Moscow state medical university»Aim of review. To consider different treatment options for dyslipidemia in non-alcoholic fatty liver disease (NAFLD). Summary. NAFLD occurs in 20-30% of adult population. In the Russian Federation its rate is estimated as high as 37,1%. In the most of NAFLD cases severe disorder of lipid metabolism takes place. In large clinical trials it was demonstrated that the dyslipidemia significantly increases cardiovascular risks and worsens life expectancy in these patients. In the present overview treatment options of several therapeutic agents for dyslipidemia treatment at NAFLD are discussed: phenofibrate, omega-3 polyunsaturated fatty acids (omega-3-PUFAs) and S-adenosylmethionine (SAM). Results of numerous experiments and several clinical trials form the basis for phenofibrate administration for NAFLD patients. In animal experiments the positive role of phenofibrate as PPARα agonist was demonstrated (Peroxisome proliferator activated receptor alpha) for NAFLD prevention and treatment. Results of several studies published at the moment demonstrate that at NAFLD lipid metabolism markers, and serum transaminase levels normalize, sensitivity to insulin increases, the liver histology pattern improves at phenofibrate treatment. Specification of efficacy and safety of application of the drug requires more large-scale clinical studies. Omega-3-PUFAs is one more option in the lipid metabolism disorders treatment in this group of patients. These substances play important role in lipid metabolism regulating expression of the genes (including PPARα) involved in lipid and glucose metabolism. Available clinical trials demonstrate high therapeutical effect of these agents at NAFLD. In the review results of the experimental studies investigating the role of SAM in NAFLD pathogenesis and disorders of lipid metabolism is presented. Conclusion. Now data on a pathogenesis of lipid metabolism disorders at NAFLD are accumulated. The bulk of experimental data and series of clinical trials allow to assume positive affect of such drugs as phenofibrate, omega-3-PUFA and SAMe for treatment of dyslipidemia. Further high-grade studies in this area is necessary.https://www.gastro-j.ru/jour/article/view/71неалкогольная жировая болезнь печенинеалкогольный стеатогепатитдислипидемияфенофибратомега-3 полиненасыщенные жирные кислотыs-аденозилметионин |
| spellingShingle | M. V. Mayevskaya M. A. Morozova Options of dyslipidemia treatment at non-alcoholic fatty liver disease Российский журнал гастроэнтерологии, гепатологии, колопроктологии неалкогольная жировая болезнь печени неалкогольный стеатогепатит дислипидемия фенофибрат омега-3 полиненасыщенные жирные кислоты s-аденозилметионин |
| title | Options of dyslipidemia treatment at non-alcoholic fatty liver disease |
| title_full | Options of dyslipidemia treatment at non-alcoholic fatty liver disease |
| title_fullStr | Options of dyslipidemia treatment at non-alcoholic fatty liver disease |
| title_full_unstemmed | Options of dyslipidemia treatment at non-alcoholic fatty liver disease |
| title_short | Options of dyslipidemia treatment at non-alcoholic fatty liver disease |
| title_sort | options of dyslipidemia treatment at non alcoholic fatty liver disease |
| topic | неалкогольная жировая болезнь печени неалкогольный стеатогепатит дислипидемия фенофибрат омега-3 полиненасыщенные жирные кислоты s-аденозилметионин |
| url | https://www.gastro-j.ru/jour/article/view/71 |
| work_keys_str_mv | AT mvmayevskaya optionsofdyslipidemiatreatmentatnonalcoholicfattyliverdisease AT mamorozova optionsofdyslipidemiatreatmentatnonalcoholicfattyliverdisease |